MedTrace Logo

Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Acquired Hemophilia A

NCT01178294 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2021-05-13

Study results available
· View outcomes & findings →

Summary

This study is to test whether the study drug (OBI-1) is safe and effective for the treatment of serious bleeding episodes in people with acquired hemophilia A.

Conditions

  • Acquired Hemophilia A

Interventions

BIOLOGICAL

OBI-1

Intravenous infusion

Sponsors & Collaborators

  • Baxalta now part of Shire

    lead INDUSTRY

Principal Investigators

  • Study Director · Takeda

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-11-10
Primary Completion
2013-07-01
Completion
2013-10-09

Countries

  • United States
  • Canada
  • India
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01178294 on ClinicalTrials.gov